Related Experiment Videos
Fosfomycin does not inhibit the tumoricidal efficacy of cisplatinum
J A Jordan1, N D Schwade, J M Truelson
1University of Texas Southwestern, Department of Otolaryngology, Dallas, USA.
Objectives:
This study investigates the effect of fosfomycin on the tumoricidal efficacy of cisplatinum.
Study Design:
Prospective study utilizing the FaDu squamous cell carcinoma cell line and a nude mouse tumor xenograft model.
Methods:
Tumor cell growth was assessed in vitro in the presence of cisplatinum and/or fosfomycin utilizing the MTT assay. An optimal cisplatinum dose and dosing schedule was established in a nude mouse tumor xenograft model of squamous cell carcinoma. Using this model, fosfomycin was tested at three dosages and tumor growth monitored over 4 weeks.
Results:
Mice treated with cisplatinum and fosfomycin had smaller tumors than those treated with cisplatinum alone (P<.01).
Conclusions:
This study is the first demonstration that fosfomycin does not inhibit the tumoricidal efficacy of cisplatinum in vivo. This suggests that fosfomycin may be useful in preventing cisplatinum-induced ototoxicity and nephrotoxicity in humans without altering the tumor response rate.